- Home
- ROIV vs HRL Comparison
ROIV vs HRL Comparison
Compare ROIV & HRL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | HRL |
|---|---|---|
| Founded | 2014 | 1891 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Meat/Poultry/Fish |
| Sector | Health Care | Consumer Staples |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 12.9B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ROIV | HRL |
|---|---|---|
| Price | $22.78 | $24.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 6 |
| Target Price | $24.31 | ★ $28.00 |
| AVG Volume (30 Days) | ★ 5.9M | 4.2M |
| Earning Date | 02-06-2026 | 02-26-2026 |
| Dividend Yield | N/A | ★ 4.76% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.87 |
| Revenue | $20,329,000.00 | ★ $12,106,160,000.00 |
| Revenue This Year | N/A | $3.43 |
| Revenue Next Year | $741.42 | $2.24 |
| P/E Ratio | ★ N/A | $28.30 |
| Revenue Growth | N/A | ★ 1.55 |
| 52 Week Low | $8.73 | $21.03 |
| 52 Week High | $23.91 | $32.07 |
Technical Indicators
Market Signals| Indicator | ROIV | HRL |
|---|---|---|
| Relative Strength Index (RSI) | 56.31 | 58.59 |
| Support Level | $22.50 | $24.14 |
| Resistance Level | $23.20 | $24.81 |
| Average True Range (ATR) | 0.75 | 0.57 |
| MACD | -0.01 | 0.11 |
| Stochastic Oscillator | 63.73 | 88.16 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About HRL Hormel Foods Corporation
Historically meat-focused, Hormel Foods broadened its lineup to include other protein offerings and became a branded food company. The firm sells its wares through multiple channels, including US retail (61.6% of fiscal 2025 sales), US foodservice (32.6%), and international (5.9%). By product, 73% of fiscal 2025 sales were from perishable food and 27% from shelf-stable. Major brands include Hormel, Spam, Jennie-O, Columbus, Applegate, Planters, and Skippy. Many of these hold the number one or two market share in their respective categories.